

PCT/EP99/07634

Mucos PHARMA GMBH & Co et al.

Our ref.: PCT1072-03196/pau

Date: September 28, 2000

Patent Claims

- 1) Use of at least one proteolytic enzyme and, optionally, of rutoside for influencing hyperactive T cells, wherein the hyperactive cells are selected from tumor antigen-specific, transplant-specific, allergen-specific and virus-specific T cells.
- 2) Use according to claim 1, characterized in that trypsin, bromelain or papain or a combination of several of said enzymes is used as the proteolytic enzyme.
- 3) Use according to claim 1 or 2, characterized in that rutoside is additionally used.
- 4) Use according to one or several of claims 1 to 3, characterized in that 20 to 100 mg bromelain, 40 to 120 mg papain and 10 to 50 mg trypsin are used per dose unit.
- 5) Use according to one or several of claims 1 to 4, characterized in that 90 mg bromelain, 120 mg papain and 100 mg rutoside x 3H₂O are used per dose unit.
- 6) Use according to one or several of claims 1 to 3, characterized in that 90 mg bromelain, 48 mg trypsin and 100 mg rutoside x 3H₂O are used per dose unit.
- 7) Use according to one or several of claims 1 to 6, characterized in that α_2 -macroglobulin is additionally used.

- Gdd A1

[illegible]